A truncated human NKG2D splice isoform negatively regulates NKG2D-Mediated function

Journal of Immunology

Volumn 193, Issue 6, 2014, Pages 2764-2771

  Karimi, Mobin A ^a,b   Aguilar, Oscar A ^c   Zou, Baixiang ^a   Bachmann, Michael H ^d   Carlyle, James R ^c   Baldwin, Cynthia L ^a   Kambayashi, Taku ^b  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DNAX ACTIVATED PROTEIN OF 10 KDA; GAMMA INTERFERON; ISOPROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG; HCST PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; SMALL INTERFERING RNA;

ARTICLE; CD8+ T LYMPHOCYTE; CELL KILLING; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION; ALTERNATIVE RNA SPLICING; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DNA SEQUENCE; GENETICS; IMMUNOLOGY; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE; SECRETION (PROCESS);

ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTEIN ISOFORMS; RECEPTORS, IMMUNOLOGIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, DNA;

EID: 84907072334     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400920     Document Type: Article

References (39)

1. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274
2. Raulet, D. H. 2003. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3: 781-790
3. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA. Science 285: 727-729
4. Cerwenka, A., A. B. Bakker, T. McClanahan, J. Wagner, J. Wu, J. H. Phillips, and L. L. Lanier. 2000. Retinoic acid early inducible genes define a ligand family for the acti vating NKG2D receptor in mice. Immunity 12: 721-727
5. Gasser, S., S. Orsulic, E. J. Brown, and D. H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190
6. Smyth, M. J., J. Swann, E. Cretney, N. Zerafa, W. M. Yokoyama, and Y. Hayakawa. 2005. NKG2D function protects the host from tumor initiation. J. Exp. Med. 202: 583-588
7. Takaki, R., Y. Hayakawa, A. Nelson, P. V. Sivakumar, S. Hughes, M. J. Smyth, and L. L. Lanier. 2005. IL-21 enhances tumor rejection through a NKG2Ddependent mechanism. J. Immunol. 175: 2167-2173
8. Diefenbach, A., E. R. Jensen, A. M. Jamieson, and D. H. Raulet. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165-171
9. Guerra, N., Y. X. Tan, N. T. Joncker, A. Choy, F. Gallardo, N. Xiong, S. Knoblaugh, D. Cado, N. M. Greenberg, and D. H. Raulet. 2008. NKG2Ddeficient mice are defective in tumor s urveillance in models of spontaneous malignancy. Immunity 28: 571-580
10. Lodoen, M., K. Ogasawara, J. A. Hamerman, H. Arase, J. P. Houchins, E. S. Mocarski, and L. L. Lanier. 2003. NKG2D -mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J. Exp. Med. 197: 1245-1253.
11. Krmpotić A.,D. H. Busch I. Bubić,F. Gebhardt,H. Hengel,M. Hasan,A. A. Scalzo,U. H. Koszinowski,S. Jonjić, 2002, MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat. Immunol, 3, 529-535.
12. Schmidt-Wolf, I. G., R. S. Negrin, H. P. Kiem, K. G. Blume, and I. L. Weissman. 1991. Use of a SCID mouse/human lymphoma model to evaluate cytokineinduced killer cells with potent antitumor cell activit y. J. Exp. Med. 174: 139-149
13. Hoyle, C., C. D. Bangs, P. Chang, O. Kamel, B. Mehta, and R. S. Negrin. 1998. Expansion of Philadelphia chromosome-negative CD3+CD56+ cytotoxic cells fro m chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92: 3318-3327
14. Alvarnas, J. C., Y. C. Linn, E. G. Hope, and R. S. Negrin. 2001. Expansion of cytotoxic CD3+CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 7: 216-222
15. Karimi, M., T. M. Cao, J. A. Baker, M. R. Verneris, L. Soares, and R. S. Negrin. 2005. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J. Immunol. 175: 7819-7828
16. Uhrberg, M., N. M. Valiante, B. P. Shum, H. G. Shilling, K. Lienert-Weidenbach, B. Corliss, D. Tyan, L. L. Lanier, and P. Parham. 1997. Human diversity in killer cell inhibi tory receptor genes. Immunity 7: 753-763
17. Diefenbach, A., E. Tomasello, M. Lucas, A. M. Jamieson, J. K. Hsia, E. Vivier, and D. H. Raulet. 2002. Selective associations with signal ing proteins determine stimulatory versus costimulatory activity of NKG2D. Nat. Immunol. 3: 1142-1149
18. Gilfillan, S., E. L. Ho, M. Cella, W. M. Yokoyama, and M. Colonna. 2002. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat. Immunol. 3: 1150-1155
19. Shum, B. P., L. R. Flodin, D. G. Muir, R. Rajalingam, S. I. Khakoo, S. Cleland, L. A. Guethlein, M. Uhrberg, and P. Parham. 2002. Conservation and variation in human and common chimpanzee CD94 and NKG2 genes. J. Immunol. 168: 240-252
20. Verneri s, M. R., M. Karami, J. Baker, A. Jayaswal, and R. S. Negrin. 2004. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103: 3065-3072
21. Reynolds, A., D. Leak e, Q. Boese, S. Scaringe, W. S. Marshall, and A. Khvorova. 2004. Rational siRNA design for RNA interference. Nat. Biotechnol. 22: 326-330
22. Glienke, J., Y. Sobanov, C. Brostjan, C. Steffens, C. Nguyen, H. Lehrach, E. Hofer, and F. Francis. 1998. The genomic organization of NKG2C, E, F, and D receptor genes in the human natural killer gene complex. Immunogenetics 48: 163-173
23. Wei, X., L. Hao, S. Ni, Q. Liu, J. Xu, and P. H. Correll. 2005. Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity. J. Biol. Chem. 280: 40241-40251
24. Wang, M. H., H. L. Fung, and Y. Q. Chen. 2000. Regulation of the RON receptor tyrosine kinase expression in macrophages: blocking the RON gene transcription by endotoxin-induced nitric oxide. J. Immunol. 164: 3815-3821
25. Tacconelli, A., A. R. Farina, L. Cappabianca, G. Desantis, A. Tessitore, A. Vetuschi, R. Sferra, N. Rucci, B. Argenti, I. Screpanti, et al. 2004. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 6: 347-360
26. Vijayakrishnan, L., J. M. Slavik, Z. Illés, R. J. Greenwald, D. Rainbow, B. Gr eve, L. B. Peterson, D. A. Hafler, G. J. Freeman, A. H. Sharpe, et al. 2004. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 20: 563-575
27. Hanawa, H., Y. Ma, S. A. Mikolajczak, M. L. Charles, T. Yoshida, R. Yoshida, C. A. Strathdee, D. W. Litchfield, and A. Ochi. 2002. A novel costimulatory signaling in human T lymphocytes by a spli ce variant of CD28. Blood 99: 2138-2145
28. Elmhurst, J. L., Z. Xie, B. F. O'Dowd, and S. R. George. 2000. The splice variant D3nf reduces ligand binding to the D3 dopamine receptor: evidence fo r heterooligomerization. Brain Res. Mol. Brain Res. 80: 63-74
29. McElvaine, A. T., and K. E. Mayo. 2006. A dominant-negative human growth hormone-releasing hormone (GHRH) receptor splice variant inhibits GHRH binding. Endocrinology 147: 1884-1894
30. Upshaw, J. L., L. N. Arneson, R. A. Schoon, C. J. Dick, D. D. Billadeau, and P. J. Leibson. 2006. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat. Immunol. 7: 5 24-532
31. Wolan, D. W., L. Teyton, M. G. Rudolph, B. Villmow, S. Bauer, D. H. Busch, and I. A. Wilson. 2001. Crystal structure of the murine NK cell-activating receptor NKG2D at 1.95 A. Nat. Immunol. 2: 248-254.
32. Li P.,D.L. Morris,B.E. Willcox,A. Steinle,T. Spies,R.K. Strong, 2001. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat. Immunol, 2. 443-451.
33. Li, P., G. McDermott, and R. K. Strong. 2002. Crystal structures of RAE-1beta and its complex with the activating immunoreceptor NKG2D. Immunity 16: 77-86
34. O'Callaghan, C. A., A. Cerwenka, B. E. Willcox, L. L. Lanier, and P. J. Bjorkman. 2001. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60. Immunity 15: 201-211
35. Steinle, A., P. Li, D. L. Morris, V. Groh, L. L. Lanier, R. K. Strong, and T. Spies. 2001. Interactions of human NKG2D with its ligands MICA,MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 53: 279-287
36. McFarland, B. J., T. Kortemme, S. F. Yu, D. Baker, and R. K. Strong. 2003. Symmetry recognizing asymmetry: analysis of the interacti ons between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands. Structure 11: 411-422
37. Garrity, D., M. E. Call, J. Feng, and K. W. Wucherpfennig. 2005. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc. Natl. Acad. Sci. USA 102: 7641-7646
38. Billadeau, D. D., J. L. Upshaw, R. A. Schoon, C. J. Dick, and P. J. Leibson. 2003. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat. Immunol. 4: 557-564
39. Leen, A. M., C. M. Rooney, and A. E. Foster. 2007. Improvi ng T cell therapy for cancer. Annu. Rev. Immunol. 25: 243-265